🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the effort against drug-resistant strains of the infection, according to scientists.

A Global Challenge

The sexually transmitted infection are on the rise around the world, with figures suggesting in excess of 82 million infections per year. Particularly high rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the face of rising global incidence, the spread of superbugs and the very limited therapeutic options presently on offer.”

Medical experts are particularly alarmed about the increase in drug-resistant strains. The WHO has designated it as a "high-priority threat". A tracking program showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Secure Authorization

Zoliflodacin, also known as a brand name, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists hope that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GSK, gained clearance in concurrent days. This medication, which is employed against urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This authorization signifies a major breakthrough in the therapy of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Data and Global Access

As per findings released by a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which combines an injection and a pill. The study included over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the authority to make available and distribute the drug in many developing nations.

Medical professionals treating patients have expressed hope. The availability of a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is deemed essential to alleviate the strain of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea around the world.